Despite the availability of around 30 anti-seizure drugs, drug-resistant epilepsy remains a significant clinical & societal burden. We report the first promising result of a new candidate BICS01.
Planegg, Germany - January 7, 2022 /PressCable/ —
Planegg / Martinsried (Germany) – Bicoll, an expert in synthesizing new and relevant small molecules as starting points for accelerated drug development, worked together with its partners at the University College London, FutureNeuro, and Royal College of Surgeons to publish data for a promising anti-seizure drug candidate BICS01 in Frontiers in Neurology.
According to the World Health Organization (WHO), Epilepsy is a chronic non-communicable disease of the brain that affects around 50 million people worldwide. It is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. Drug-resistant epilepsy remains a significant clinical and societal burden, with one-third of people with epilepsy continuing to experience seizures despite the availability of around 30 anti-seizure drugs (ASDs). This figure may be as high as 3 out of 4 in patients with temporal lobe epilepsy (TLE). In addition, many ASDs can have significant adverse effects which may severely impact a person’s quality of life.
Gareth Morris et al. report the preliminary preclinical evaluation of BICS01, a synthetic product based on a natural compound that Bicoll scientist pre-selected, as a potential ASD. In the experiments, BICS01 showed low toxicity and was well tolerated following systemic injection at up to 1,000 mg/kg. The results indicate that BICS01 is able to acutely reduce epileptiform activity in hippocampal networks. In conclusion, BICS01 has promising anti-seizure effects with seemingly limited impact on normal hippocampal function. Further studies are required to translate these findings to achieve in vivo efficacy and to ultimately build up a full preclinical profile for BICS01.
The article is available now at: https://www.frontiersin.org/articles/10.3389/fneur.2021.791608/full .
About Bicoll
The Bicoll Group is a privately-owned biopharmaceutical company which includes Bicoll GmbH headquartered near Munich in Planegg / Martinsried, Germany, and its wholly-owned subsidiary Bicoll Biotechnology (Shanghai) Co. Ltd.
Bicoll offers pre-clinical support with an efficient, multi-disciplinary approach to drug discovery. Dedicated to the discovery and optimization of the highest quality lead compounds, Bicoll provides services to international clients in the pharmaceutical, agrochemical, and related industries. The unique combination of expertise in high-tech natural product chemistry and medicinal chemistry enables Bicoll to increase the quality and quantity of the drug discovery pipeline of partner’s candidate portfolios. For more information: https://bicoll-group.com/
Contact Info:
Name: Maria Lamottke
Email: Send Email
Organization: Bicoll GmbH
Address: 19 Am Klopferspitz, Planegg, Bayern 82152, Germany
Phone: +49-89-82010630
Website: https://bicoll-group.com
Source: PressCable
Release ID: 89059186
